 |
10 Diseases |  |
1 Trial |
|
1 Trial |  |
32 News |  |
- | AST-301 / University of Washington, Aston Sci., EpiThany
Trial completion: Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer (clinicaltrials.gov) - Apr 7, 2025
P1, N=66, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed
- | AST-301 / University of Washington, Aston Sci., EpiThany
Trial completion date: Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer (clinicaltrials.gov) - Feb 6, 2025
P1, N=66, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Trial completion date: Dec 2024 --> Apr 2025
- AST-301 / University of Washington, Aston Sci., EpiThany
Humor Me With Calcium: A Rare Presentation of Humoral Hypercalcemia of Malignancy Secondary to Cholangiocarcinoma (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_4077;
The hypercalcemia improved with fluids and pamidronate...There is also pericholecystic fluid noted, likely related to ascites. There is no visible evidence of biliary ductal dilatation in either view.
- | AST-301 / University of Washington, Aston Sci., EpiThany
Trial primary completion date: Conerstone3: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer (clinicaltrials.gov) - Jul 9, 2024
P2, N=24, Recruiting, Sponsor: Aston Sci. Inc.
There is no visible evidence of biliary ductal dilatation in either view. Trial primary completion date: Oct 2023 --> Oct 2025
- | AST-301 / University of Washington, Aston Sci., EpiThany
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Cornerstone001: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer (clinicaltrials.gov) - Jun 16, 2024
P2, N=10, Terminated, Sponsor: Aston Sci. Inc.
Trial primary completion date: Oct 2023 --> Oct 2025 N=146 --> 10 | Trial completion date: Dec 2025 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Aug 2025 --> May 2024; Difficulty in recruiting patients
- AST-301 / University of Washington, Aston Sci., EpiThany
AST-301,a pDNA-based cancer vaccine encoding HER2-ICD, enhances anti-tumor effect of HER2-ADC in a HER2-expressed gastric cancer xenograft model (Section 5) - Mar 5, 2024 - Abstract #AACR2024AACR_6951;
With combining AST-301 and HER2 ADCs, it was demonstrated that anti-tumor effect was likely synergistic in the athymic mouse model. Phase 2 study of AST-301 in HER2-expressed gastric cancer has been on going (CornerStone-003, NCT 05771584).
- AST-301 / University of Washington, Aston Sci., EpiThany
AST-301, a pDNA-based cancer vaccine encoding HER2-ICD, enhances anti-tumor effect of HER2-ADC in a HER2-expressed gastric cancer xenograft model (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1220;
Immunologically, the combination of AST-301 and HER2 ADCs suppressed the increase of MDSC in the tumor environment. Based on those supporting data, phase 2 study of AST-301 in HER2-expressed gastric cancer has been active (CornerStone-003, NCT#05771584).
- AST-301 / University of Washington, Aston Sci., EpiThany
Antitumor effect of HER2-hICD vaccine combining with HER2 ADC depending on T cell existence in a mouse model: pooled analysis (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_365;
P1
Conclusions Given that clear antitumor effect of AST-301-based regimen was observed in CD34+ humanized mouse model than athymic BALB/c nude mouse model, it is proven that the presence of T cells is very crucial in pharmacological efficacy of cancer vaccine approach and relevant in-vivo efficacy study. These translational researches are supporting a clinical study of AST-301 combining with HER2-ADCs.
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma, AST-301 / University of Washington, Aston Sci., EpiThany
PSC in an Acutely Psychotic Patient (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1499;
These translational researches are supporting a clinical study of AST-301 combining with HER2-ADCs. He was found to have elevated liver enzymes
- || AST-301 / University of Washington, Aston Sci., EpiThany
Enrollment open: Conerstone3: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer (clinicaltrials.gov) - Jul 20, 2023
P2, N=24, Recruiting, Sponsor: Aston Sci. Inc.
He was found to have elevated liver enzymes Not yet recruiting --> Recruiting
- | AST-301 / University of Washington, Aston Sci., EpiThany
Trial completion, IO biomarker: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Apr 18, 2023
P1/2, N=31, Completed, Sponsor: University of Washington
Not yet recruiting --> Recruiting Unknown status --> Completed
- AST-301 / University of Washington, Aston Sci., EpiThany
AST-301, a pDNA-based therapeutic cancer vaccine encoding HER2 ICD, improves the efficacy of checkpoint blockade therapy in CD34+ humanized gastric cancer mouse model (Section 24; Poster Board #29) - Mar 14, 2023 - Abstract #AACR2023AACR_2614;
P1
Currently, we are ongoing study to prove the anti-tumor synergistic effects of the combination of AST-301 and various FDA-approved Antibody Drug Conjugates (ADCs). This effort is focused on narrowing the administration doses to low levels to resolve the safety issue of ADC or ICI, and it will strongly support the diverse applicability of the cancer therapeutic vaccine.
- ||| AST-301 / University of Washington, Aston Sci., EpiThany
Enrollment open: Cornerstone001: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer (clinicaltrials.gov) - May 5, 2022
P2, N=146, Recruiting, Sponsor: Aston Sci. Inc.
This effort is focused on narrowing the administration doses to low levels to resolve the safety issue of ADC or ICI, and it will strongly support the diverse applicability of the cancer therapeutic vaccine. Not yet recruiting --> Recruiting
- AST-301 / University of Washington, Aston Sci., Herceptin (trastuzumab) / Roche
The anti-tumor activity of HER-2/neu ICD therapeutic cancer vaccine (AST-301, pNGVL3-hICD) in Her2-expressed gastric cancer xenograft model (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_1112;
P1
Conclusions Tumor protective and tumor therapeutic effect of AST-301 were demonstrated well in various doses and regimens on HER2/neu positive gastric cancer xenograft model. These data would be supporting a proof of concept (PoC) clinical study of HER-2/neu ICD therapeutic cancer vaccine in certain type of HER2/neu-expressed gastric cancer patient.
- | AST-301 / University of Washington, Aston Sci., EpiThany
Trial completion date: Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer (clinicaltrials.gov) - Oct 12, 2020
P1, N=66, Active, not recruiting, Sponsor: University of Washington
These data would be supporting a proof of concept (PoC) clinical study of HER-2/neu ICD therapeutic cancer vaccine in certain type of HER2/neu-expressed gastric cancer patient. Trial completion date: Dec 2023 --> Dec 2024
- | AST-301 / University of Washington, Aston Sci., EpiThany
Trial completion: Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer (clinicaltrials.gov) - Feb 10, 2020
P2, N=38, Completed, Sponsor: University of Washington
Trial completion date: Dec 2023 --> Dec 2024 Active, not recruiting --> Completed
- | AST-301 / University of Washington, Aston Sci., EpiThany
Enrollment closed, IO biomarker: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Oct 2, 2017
P1/2, N=31, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- AST-301 / University of Washington, Aston Sci., EpiThany
Enrollment open, Trial primary completion date, IO biomarker: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Jan 23, 2017
P1/2, N=30, Recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting Suspended --> Recruiting | Trial primary completion date: Mar 2017 --> Mar 2018
- AST-301 / University of Washington, Aston Sci., EpiThany
Trial primary completion date, IO biomarker: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Sep 7, 2016
P1/2, N=30, Suspended, Sponsor: University of Washington
Suspended --> Recruiting | Trial primary completion date: Mar 2017 --> Mar 2018 Trial primary completion date: Sep 2016 --> Mar 2017
- AST-301 / University of Washington, Aston Sci., EpiThany
Trial primary completion date, IO biomarker: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=30, Suspended, Sponsor: University of Washington
Trial primary completion date: Sep 2016 --> Mar 2017 Trial primary completion date: Sep 2015 --> Sep 2016
- AST-301 / University of Washington, Aston Sci., EpiThany
Trial suspension, IO biomarker: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=30, Suspended, Sponsor: University of Washington
Trial primary completion date: Sep 2015 --> Sep 2016 Recruiting --> Suspended
- AST-301 / University of Washington, Aston Sci., EpiThany
Trial primary completion date: Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer (clinicaltrials.gov) - Apr 14, 2015
P2, N=38, Active, not recruiting, Sponsor: University of Washington
Recruiting --> Suspended Trial primary completion date: Feb 2015 --> Jul 2015
- AST-301 / University of Washington, Aston Sci., EpiThany
Trial initiation date, IO biomarker: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Mar 11, 2014
P1/2, N=30, Recruiting, Sponsor: University of Washington
Trial primary completion date: Feb 2015 --> Jul 2015 Initiation date: Nov 2013 --> Feb 2014
- AST-301 / University of Washington, Aston Sci., EpiThany
Enrollment open, IO biomarker: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Mar 11, 2014
P1/2, N=30, Recruiting, Sponsor: University of Washington
Initiation date: Nov 2013 --> Feb 2014 Not yet recruiting --> Recruiting
- AST-301 / University of Washington, Aston Sci., EpiThany
Trial completion, Metastases: Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2 (clinicaltrials.gov) - Oct 10, 2013
P=N/A, N=56, Completed, Sponsor: University of Washington
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- AST-301 / University of Washington, Aston Sci., EpiThany
New P1/2 trial, IO biomarker: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Aug 12, 2013
P1/2, N=30, Recruiting, Sponsor: University of Washington
- AST-301 / University of Washington, Aston Sci., EpiThany
Trial completion, Metastases: Biological Therapy in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Mar 25, 2013
P=N/A, N=3, Completed, Sponsor: Duke University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- AST-301 / University of Washington, Aston Sci., EpiThany
Enrollment change: Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer (clinicaltrials.gov) - Jan 23, 2012
P2, N=38, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed N=52 --> 38